Indications and uses
relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor
Ranitidine 75 mg (as ranitidine hydrochloride USP, 84 mg)
Acid reducer
Allergy alert: Do not use if you are allergic to ranitidine or other acid reducers
Ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Colloidal silicon dioxide, croscarmellose sodium, hypromellose, iron oxide red, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, talc, titanium dioxide
Call 1-800-406-7984
†Compare to the active ingredient of Zantac 75®
Best Choice®Brand
Regular Strength
ACID REDUCER
RANITIDINE TABLETS, USP 75 mg/ACID REDUCER
PREVENTS & RELIEVES HEARTBURN associated with acid indigestion and sour stomach
60 Tablets
DISTRIBUTED BY: VALU MERCHANDISERS, CO.
5095000/0412

| Class | Version | Type | Effective |
|---|---|---|---|
| RANITIDINE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 7f54af34-be54-4c3c-894f-78df6452d747 | Product name | 3 | 20190703 |
| ccf8541e-b7dc-e6ba-06c9-15bf143a7850 | Product name | 5 | 20190611 |
| 05700d9e-ea6f-4aab-b0ed-1488f1d85d7b | Product name | 1 | 20180904 |
| 2f9d4e5c-e179-490e-8c43-f19e1e0ca228 | Product name | 1 | 20160720 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 63941-352-30 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-88de-f424-e053-dadaa90a57ce | Drug Facts |
| 63941-352-60 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-88de-f424-e053-dadaa90a57ce | Drug Facts |
| 63941-352-69 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-88de-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63941-352-30 | Ranitidine | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 1 | |
| 63941-352-60 | Ranitidine | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 1 | |
| 63941-352-69 | Ranitidine | 10 in 1 BLISTER PACK | TABLET, FILM COATED | 10 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| RANITIDINE HYDROCHLORIDE | ACTIVE INGREDIENT | BK76465IHM | 1 | |
| RANITIDINE | ACTIVE MOIETY | 884KT10YB7 | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| COLLOIDAL SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 1 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| POLYETHYLENE GLYCOL 400 | INACTIVE INGREDIENT | B697894SGQ | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 63941-352 | 63941-352-69, 63941-352-30, 63941-352-60 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| RANITIDINE HYDROCHLORIDE | BK76465IHM | ACTIM |
| COLLOIDAL SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| HYPROMELLOSES | 3NXW29V3WO | IACT |
| FERRIC OXIDE RED | 1K09F3G675 | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| POLYETHYLENE GLYCOL 400 | B697894SGQ | IACT |
| TALC | 7SEV7J4R1U | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | EMULSION / TOPICAL | 1.2 %w/w | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | SUPPOSITORY / VAGINAL | 30 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SUSPENSION / ORAL | 4441 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | GRANULE, FOR SUSPENSION / ORAL | 282 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / SUBLINGUAL | 10 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, LIQUID FILLED / ORAL | 106 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | LOTION / TOPICAL | 5 %w/w | ||
| TALC | TALC | 7SEV7J4R1U | POWDER / TOPICAL | 9235 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| TALC | TALC | 7SEV7J4R1U | LOZENGE / ORAL | 50 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, EXTENDED RELEASE / ORAL | 1472 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 60 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | PELLET / ORAL | 162 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | NA | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | SOLUTION / ORAL | 70200 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET / ORAL | 193 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / ORAL | 305 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 357 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | GEL / RECTAL | 348 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CREAM / TOPICAL | NA | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, EXTENDED RELEASE / ORAL | 5119 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | CAPSULE / ORAL | 1488 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | INJECTION / INTRAMUSCULAR | 1 %w/v | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | CAPSULE / ORAL | 13440 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | SWAB / TOPICAL | 5250 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FOR SUSPENSION / ORAL | 24 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, FILM COATED / ORAL | 20 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | CREAM / TOPICAL | 10 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SHAMPOO, SUSPENSION / TOPICAL | 3 %w/v | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | FILM, SOLUBLE / ORAL | 29 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| TALC | TALC | 7SEV7J4R1U | SUSPENSION / ORAL | 234 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / SUBLINGUAL | 43.2 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, DELAYED RELEASE / ORAL | 105 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 18 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | CONCENTRATE / ORAL | 3000 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A201745-001 | RANITIDINE HYDROCHLORIDE | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A201745-001 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | 2012-02-29 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| c369afdb-43ba-482b-a051-83c42c09a64a | 3df3e0ca-3e78-447c-b650-82bf11110c01 | 2013-01-31 | Warnings | c369afdb-43ba-482b-a051-83c42c09a64a 3df3e0ca-3e78-447c-b650-82bf11110c01 |
Adverse event summaries are temporarily unavailable. Other product information remains available.